Health economics and outcomes research within drug development
Abstract
Healthcare decision makers who determine funding for new medical technologies depend on manufacturers to provide evidence of the technology's efficacy, safety and cost-effectiveness. Constrained budgets and increasing reliance on formal health technology assessment (HTA) have created an abundance of external hurdles that manufacturers must navigate to ensure successful product commercialization. These demands have pushed pharmaceutical companies to adjust their internal structures to coordinate generation of appropriate evidence. In this article we summarize internal and external opportunities for manufacturers to establish a foundation of evidence for successful market access, starting in Phase I of development and continuing throughout the post-approval product lifecycle.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The four financing decisions differ in how directly they are informed by research on health economics and outcomes versus market access.
“They also differ in how directly they are informed by research on (a) health economics and outcomes, principally economic evaluations, versus (b) market access, which considers issues of efficiency in service delivery—including how best to pay for an innovation [27].”
From Translating economic evaluations into financing strategies for implementing evidence-based practices (2021) · cites this paper as [27]
Cites
Carlson, J. J., Sullivan, S. D., Garrison, L. P., Neumann, P. J., & Veenstra, D. L. (2010) · Health Policy · doi:10.1016/j.healthpol.2010.02.005 · Cited by 287 · see citing works
Eddy, D. M. (1990) · JAMA · doi:10.1001/jama.1990.03440030128037 · Cited by 264 · see citing works
Adamski, J., Godman, B., Ofierska-Sujkowska, G., et al. (2010) · BMC Health Services Research · doi:10.1186/1472-6963-10-153 · Cited by 258 · see citing works
Evidence and Value: Impact on DEcisionMaking – the EVIDEM framework and potential applications
Goetghebeur, M. M., Wagner, M., Khoury, H., Levitt, R. J., Erickson, L. J., & Rindress, D. (2008) · BMC Health Services Research · doi:10.1186/1472-6963-8-270 · Cited by 232 · see citing works
Jewell, C. J., & Bero, L. A. (2008) · Milbank Quarterly · doi:10.1111/j.1468-0009.2008.00519.x · Cited by 192 · see citing works
Clinical decision making: from theory to practice. Anatomy of a decision
Eddy, D. M. (1990) · JAMA · doi:10.1001/jama.263.3.441 · Cited by 179 · see citing works
Relative efficacy of drugs: an emerging issue between regulatory agencies and third-party payers
Eichler, H., Bloechl‐Daum, B., Abadie, E., Barnett, D. B., König, F., & Pearson, S. D. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3079 · Cited by 174 · see citing works
Tunis, S. (2007) · Health Affairs · doi:10.1377/hlthaff.26.4.w500 · Cited by 71 · see citing works
The Critical Role Of Observational Evidence In Comparative Effectiveness Research
Fleurence, R., Naci, H., & Jansen, J. P. (2010) · Health Affairs · doi:10.1377/hlthaff.2010.0630 · Cited by 68 · see citing works
Medicare’s National Coverage Decisions For Technologies, 1999–2007
Neumann, P. J., Kamae, M. S., & Palmer, J. A. (2008) · Health Affairs · doi:10.1377/hlthaff.27.6.1620 · Cited by 63 · see citing works
Motola, D., Ponti, F. D., Rossi, P., et al. (2005) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2004.02320.x · Cited by 60 · see citing works
A Flexible Approach To Evidentiary Standards For Comparative Effectiveness Research
Garrison, L. P., Neumann, P. J., Radensky, P. W., et al. (2010) · Health Affairs · doi:10.1377/hlthaff.2010.0692 · Cited by 17 · see citing works
US healthcare reform: implications for health economics and outcomes research
Chambers, J. D., & Neumann, P. J. (2010) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1586/erp.10.32 · Cited by 9 · see citing works
What is a truly innovative drug? New definition from the International Society of Drug Bulletins.
Kopp, C. (2002) · PubMed · Cited by 5 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Translating economic evaluations into financing strategies for implementing evidence-based practices
Dopp, A. R., Kerns, S. E. U., Panattoni, L., Ringel, J. S., Eisenberg, D., Powell, B. J., Low, R., & Raghavan, R. (2021) · Implementation Science · doi:10.1186/s13012-021-01137-9 · Cited by 52 · see citing works
- Authors
- van Nooten, F., Holmstrom, S., Green, J., Wiklund, I., Odeyemi, I. A. O., & Wilcox, T. K.
- Affiliations
- United BioSource Corporation (United Kingdom) (GB)
- Astellas Pharma (United Kingdom) (GB)
- Venue
- Drug Discovery Today
- Publisher
- Elsevier BV
- Published
- 2012-06
- Volume
- 17
- Issue
- 11-12
- Pages
- 615-622
- ISSN
- 1359-6446 (ISSN-L)
- OpenAlex
- W2213466407
- Cited by
- 40
- References
- 14
- Citations by year
- 2026: 4 · 2025: 2 · 2024: 2 · 2023: 4 · 2022: 3 · 2021: 3 · 2020: 3 · 2018: 2 · 2017: 4 · 2016: 3 · 2015: 4 · 2014: 4 · 2013: 2
- FWCI
- 1.22
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Drug Discovery Today (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmaceutical industry and healthcare
- Keywords
- health economics, outcomes research, drug development, health technology assessment, market access, pharmaceutical industry, cost-effectiveness, evidence generation, product life cycle
- MeSH terms
- Biopharmaceutics, Cost-Benefit Analysis, Humans, Insurance, Health, Reimbursement, Technology Assessment, Biomedical, Randomized Controlled Trials as Topic, Outcome Assessment, Health Care, Marketing, Drug Discovery, Comparative Effectiveness Research
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
